Financials Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 11/12/2024 GMT			5-day change	1st Jan Change
254.15 ^USD	+0.09%		-0.22%	+32.78%

12-05	Alnylam Pharmaceuticals, Inc. Presents at Piper Sandler 36th Annual Healthcare Conference, Dec-05-2024 11:00 AM
12-03	TransMedics Names Gerardo Hernandez as CFO; Shares Fall	MT

Projected Income Statement: Alnylam Pharmaceuticals, Inc.

income-statement-evolution-chart ALNYLAM-PHARMACEUTICALS-I

Fiscal Period: Dezember	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	219.8	492.9	844.3	1,037	1,828	2,243	2,606	3,488
Change	-	124.28%	71.31%	22.88%	76.23%	22.7%	16.15%	33.87%
EBITDA ¹	-885.1	-793.7	-661.1	-740.6	-228.1	-77.11	-31.79	915.4
Change	-	-10.33%	-16.7%	12.03%	-69.2%	66.2%	58.78%	-
EBIT ¹	-939.4	-828.4	-708.7	-785.1	-282.2	-128	-84.77	493.8
Change	-	-11.81%	-14.46%	10.78%	-64.06%	54.63%	33.78%	-
Interest Paid ¹	-	-27.16	-143.5	-156	-121.2	-124.4	-106.8	-112.6
Earnings before Tax (EBT) ¹	-885.3	-855.6	-852.1	-1,127	-433.5	-261.5	-189.7	368.5
Change	-	-3.35%	-0.4%	32.25%	-61.53%	39.68%	27.47%	-
Net income ¹	-886.1	-858.3	-852.8	-1,131	-440.2	-259	-195.1	375.1
Change	-	-3.14%	-0.64%	32.64%	-61.08%	41.18%	24.64%	-
Announcement Date	06/02/20	11/02/21	10/02/22	23/02/23	15/02/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: Diciembre	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	71.68	99.48	104	125.9	163.6	177.6	220.6	187.6	258.5	213.3	224.8	264.3	335	319.3	318.8	750.5	439.7	494.3	659.8	500.9	579.3	558.4	582.1	630.8	760
Change	-	38.78%	4.51%	21.06%	29.96%	8.56%	24.21%	-14.93%	37.79%	-17.51%	5.42%	17.56%	26.76%	-4.7%	-0.17%	135.46%	-41.41%	12.42%	33.48%	-24.08%	15.64%	-3.61%	4.26%	8.35%	20.48%
EBITDA ¹	-	-193.2	-190.7	-216.6	-183.8	-173.7	-134.4	-169.9	-183.2	-137.3	-181.6	-247.4	-174.3	-135.7	-216.7	227.2	-102.9	-29.92	63.62	-	-56.1	-	-	-	-
Change	-	-	-1.29%	13.62%	-15.14%	-5.54%	-22.63%	26.45%	7.83%	-25.06%	32.28%	36.26%	-29.56%	-22.12%	59.61%	-	-	-70.93%	-	-100%	-	100%	-	-	-
EBIT ¹	-298.1	-210.2	-198.9	-225.2	-194.2	-186.3	-146.2	-181.7	-194.6	-146.7	-191.7	-258	-188.6	-149.8	-229.8	213.9	-116.4	-43.44	48.61	-76.9	-62.75	-73.99	-74.64	-40.1	85.78
Change	-	-29.49%	-5.38%	13.25%	-13.76%	-4.1%	-21.53%	24.3%	7.09%	-24.58%	30.64%	34.62%	-26.91%	-20.57%	53.42%	-	-	-62.69%	-	-	18.4%	-17.9%	-0.89%	46.28%	-
Charge d'intérêts ¹	-	-	-	-27.25	-49.38	-13.02	-42.17	-22.56	-65.74	-41.35	-42.61	-41.08	-29.91	-28.96	-30.04	-30.89	-31.34	-35.25	-33.26	-34.38	-27.32	-28	-37	-55	-65
Earnings before Tax (EBT) ¹	-276.6	-181.6	-177.9	-252.5	-243.6	-199.3	-188.3	-204.2	-260.3	-239.4	-274.7	-405.9	-207	-172.4	-274.2	150.7	-137.7	-63.59	-11.17	-108.7	-70.29	-94.1	-95.7	-64.29	49.43
Change	-	-34.32%	-2.06%	41.9%	-3.51%	-18.2%	-5.49%	8.45%	27.45%	-8.05%	14.76%	47.79%	-49%	-16.74%	59.09%	-	-	-53.82%	-82.44%	873.07%	35.31%	-33.87%	-1.7%	32.81%	-
Net income ¹	-276.2	-182.2	-179.2	-253.3	-243.5	-200.3	-189.6	-204.5	-258.5	-240.3	-277.4	-405.9	-207.5	-174.1	-276	147.8	-137.9	-65.94	-16.89	-111.6	-77.21	-103.8	-107.7	-73.32	32.22
Change	-	-34.02%	-1.64%	41.32%	-3.85%	-17.76%	-5.36%	7.89%	26.38%	-7.01%	15.42%	46.33%	-48.88%	-16.09%	58.54%	-	-	-52.18%	-74.39%	560.61%	30.79%	-34.46%	-3.74%	31.92%	-
Announcement Date	06/02/20	06/05/20	06/08/20	05/11/20	11/02/21	29/04/21	03/08/21	28/10/21	10/02/22	28/04/22	28/07/22	27/10/22	23/02/23	04/05/23	03/08/23	02/11/23	15/02/24	02/05/24	01/08/24	31/10/24	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Alnylam Pharmaceuticals, Inc.

balance-sheet-analysis-chart ALNYLAM-PHARMACEUTICALS-I

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-547	-1,683	-1,760	-1,105	-41.4	-1,742	-1,341	-1,601
Change	-	-407.68%	-204.58%	-162.78%	-103.75%	-4,311.09%	-176.98%	-219.39%
Announcement Date	06/02/20	11/02/21	10/02/22	23/02/23	15/02/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Alnylam Pharmaceuticals, Inc.

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	140.2	70.36	76.37	72.06	62.21	55.62	83.39	111.4
Change	-	-49.8%	8.54%	-5.65%	-13.67%	-10.6%	49.93%	33.55%
Free Cash Flow (FCF) ¹	-418.6	-685.3	-718.1	-613.3	41.94	-30.17	74.54	710
Change	-	63.72%	4.78%	-14.59%	-106.84%	-171.92%	-347.08%	852.5%
Announcement Date	06/02/20	11/02/21	10/02/22	23/02/23	15/02/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Alnylam Pharmaceuticals, Inc.

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-402.76%	-161.04%	-78.3%	-71.39%	-12.48%	-3.44%	-1.22%	26.24%
EBIT Margin (%)	-427.5%	-168.09%	-83.93%	-75.68%	-15.43%	-5.71%	-3.25%	14.16%
EBT Margin (%)	-402.85%	-173.6%	-100.93%	-108.63%	-23.71%	-11.66%	-7.28%	10.56%
Net margin (%)	-403.24%	-174.15%	-101.01%	-109.04%	-24.08%	-11.54%	-7.49%	10.75%
FCF margin (%)	-190.48%	-139.05%	-85.05%	-59.12%	2.29%	-1.34%	2.86%	20.35%
FCF / Net Income (%)	47.24%	79.85%	84.2%	54.22%	-9.53%	11.65%	-38.2%	189.28%
Profitability
ROA	-44.64%	-29.58%	-24.19%	-31.47%	-11.94%	-2.48%	-2.38%	7.75%
ROE	-53.42%	-69.92%	-106.31%	-526.14%	-	-12.44%	134.95%	109.24%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	63.78%	14.28%	9.05%	6.95%	3.4%	2.48%	3.2%	3.19%
CAPEX / EBITDA (%)	-15.84%	-8.87%	-11.55%	-9.73%	-27.27%	-72.13%	-262.34%	12.17%
CAPEX / FCF (%)	-33.48%	-10.27%	-10.64%	-11.75%	148.32%	-184.37%	111.88%	15.69%
Items per share
Cash flow per share ¹	-	-5.348	-5.417	-4.448	0.8339	1.672	2.13	-
Change	-	-	1.3%	-17.89%	-118.75%	100.5%	27.38%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	12.82	8.729	4.894	-1.277	-1.754	0.4022	1.471	7.784
Change	-	-31.93%	-43.93%	-126.09%	37.37%	-122.93%	265.65%	429.33%
EPS ¹	-8.11	-7.46	-7.2	-9.3	-3.52	-2.021	-1.33	3.008
Change	-	-8.01%	-3.49%	29.17%	-62.15%	-42.6%	-34.18%	-326.16%
Nbr of stocks (in thousands)	111,490	116,181	119,601	123,028	125,493	128,981	128,981	128,981
Announcement Date	06/02/20	11/02/21	10/02/22	23/02/23	15/02/24	-	-	-